GET DAILY SIGNALSThe Joint Corp. (JYNT) Q3 2026 Earnings: Modest Revenue Rise Offset by Lowered Sales Guidance
Key Takeaways
- The Joint Corp. reported third-quarter 2026 revenue of $13.6 million, up about 1% year over year but below consensus estimates near $14.85 million.
- System-wide sales declined 3.1% to $123.3 million, while comparable sales (comp sales) improved to -1.9% from -2.8% in the prior quarter.
- Consolidated diluted EPS was $(0.01), driven by a loss from discontinued operations; diluted EPS from continuing operations was $0.10.
- Adjusted EBITDA from continuing operations rose to $2.3 million from $1.4 million a year ago, reflecting the shift to a capital-light franchisor model.
- Management lowered its full-year 2026 system-wide sales outlook to $508 million–$512 million, citing macroeconomic pressure on consumer spending.
- Additional detail on the ticker's Major News, Today's Price Move, Price Targets, and Forecast is available on dedicated pages.
- Explore Trending AI Robots to see AI-driven trading strategies and signals across the market.
Earnings Context and Why It Matters
The Joint Corp. (JYNT) is the nation's largest franchisor of chiropractic clinics through its The Joint Chiropractic network, operating on a cash-based, non-insurance model. Its third-quarter 2026 results arrive as the company completes a multi-year transition to a pure-play franchisor, refranchising its remaining company-owned and managed clinics. This shift has improved profitability and cash generation from continuing operations, even as system-wide sales and comp sales remain under pressure from softer consumer spending. Investors are watching whether the leaner operating structure can convert future growth into earnings while management works to restore consistent top-line momentum across roughly 930 locations.
Reported Results
For the third quarter ended September 30, 2026, The Joint Corp. (JYNT) reported total revenue of $13.6 million, a modest increase from $13.4 million in the prior-year period but below the consensus estimate of roughly $14.85 million. Royalty fees rose 2% to $8.3 million, outpacing system-wide sales as refranchised clinics generated royalties not present a year earlier. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
System-wide sales were $123.3 million, down 3.1% year over year, while comp sales improved to -1.9% from -2.8% in the second quarter of 2026. Consolidated net loss was $117,000, or $0.01 per diluted share, compared with consolidated net income of $855,000, or $0.06 per diluted share, in the prior-year quarter; the swing reflected a $1.6 million loss from discontinued operations. Diluted EPS from continuing operations was $0.10, up from $0.02 a year earlier.
Adjusted EBITDA from continuing operations increased to $2.3 million from $1.4 million, while consolidated Adjusted EBITDA held steady at $3.3 million. The company ended the quarter with unrestricted cash of $18.3 million and an undrawn $20 million credit line.
Market Reaction and Investor Sentiment
The stock has faced a challenging backdrop, with shares down more than 11% over the three months heading into the report and trading near multi-year lows amid persistent macroeconomic headwinds on consumer spending. Post-earnings reaction is likely to hinge on two competing signals: continued improvement in profitability from the refranchising effort versus a top line that remains under pressure. The lowered full-year guidance on system-wide sales, combined with plans to close underperforming franchised clinics that could leave year-end clinic count roughly 50 below 2025 levels, underscores the cautious tone management is signaling about near-term demand.
Forward Outlook and Key Factors to Monitor
Management updated its 2026 guidance, narrowing expectations as consumer spending pressures persist. System-wide sales are now projected at $508 million to $512 million, down from the prior range of $519 million to $552 million. Comp sales for clinics open 13 months or more are now expected between -3.5% and -2.5%, versus the previous -3% to 3% range.
Consolidated Adjusted EBITDA guidance was left unchanged at $12.5 million to $13.5 million, signaling confidence that cost discipline and the franchisor model can protect profitability even on a softer top line. Investors should watch how the company balances profitability with growth as it closes underperforming clinics while supporting franchisee performance.
Key factors ahead include the completion of ownership transfers for the remaining 15 company-owned or managed clinics, the trajectory of active membership count and lifetime value per member, and any impact from lower average patient spend and fewer new patients. Free cash flow generation, which was negative in the quarter partly due to a legal settlement payment, will also be a focal point as the company expects improvement once remaining transfers conclude.
Refining Research with Tickeron’s AI Tools
In my analysis, I turned to Tickeron’s AI Screener to quickly filter for stocks matching similar earnings and franchisor-model criteria. It surfaces technical patterns, fundamentals, and AI signals efficiently, helping me cross-check ideas without manual effort. This tool has become a regular part of my workflow for earnings reviews like this one, offering a structured way to spot comparable opportunities across sectors.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Momentum Indicator for JYNT turns positive, indicating new upward trend
JYNT saw its Momentum Indicator move above the 0 level on October 22, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 107 similar instances where the indicator turned positive. In 84 of the 107 cases, the stock moved higher in the following days. The odds of a move higher are at 79%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where JYNT's RSI Oscillator exited the oversold zone, 29 of 38 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 76%.
The Moving Average Convergence Divergence (MACD) for JYNT just turned positive on October 19, 2026. Looking at past instances where JYNT's MACD turned positive, the stock continued to rise in 32 of 41 cases over the following month. The odds of a continued upward trend are 78%.
Following a +2.01% 3-day Advance, the price is estimated to grow further. Considering data from situations where JYNT advanced for three days, in 158 of 235 cases, the price rose further within the following month. The odds of a continued upward trend are 67%.
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where JYNT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
JYNT broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for JYNT entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 48 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 70 (best 1 - 100 worst), indicating slightly worse than average price growth. JYNT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 74 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.576) is normal, around the industry mean (204.059). P/E Ratio (28.346) is within average values for comparable stocks, (18.581). Projected Growth (PEG Ratio) (0.140) is also within normal values, averaging (2.498). Dividend Yield (0.000) settles around the average of (0.091) among similar stocks. P/S Ratio (2.154) is also within normal values, averaging (2.688).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. JYNT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 82, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
an operator of chiropractic care clinics
Industry HospitalNursingManagement
Advertisement